Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|7|4|431-454

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.7, Iss.4, 2006-05, pp. : 431-454

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity

By  

Current Drug Metabolism, Vol. 12, Iss. 10, 2011-12 ,pp. : 932-943

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of irinotecan toxicity

By Marsh Sharon   McLeod Howard L  

Pharmacogenomics, Vol. 5, Iss. 7, 2004-10 ,pp. : 835-843

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review

By  

Current Clinical Pharmacology, Vol. 5, Iss. 3, 2010-08 ,pp. : 209-217

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications

By  

Current Drug Metabolism, Vol. 7, Iss. 6, 2006-08 ,pp. : 677-685

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Mechanisms of Benefit with Thalidomide in Chronic Heart Failure

By Aukrust Pål   Yndestad Arne  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 2, 2007-01 ,pp. : 127-134

Adis International

Access to resources Recommend Favorite